SCHEMBL22149121

SCHEMBL22149121

COc1cc(Nc2ccc3ncc(-c4cccc(N5CCNCC5)c4)nc3c2)cc(OC)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.60
FGFR3 P22607 4/20 0.60
HTR7 P34969 3/20 0.47
HTR1A P08908 2/20 0.47
ADRB1 P08588 2/20 0.46
CAMK2D Q13557 1/20 0.46
FGFR1 P11362 2/20 0.45
FGFR2 P21802 2/20 0.45
FGFR4 P22455 2/20 0.45
KARS1 Q15046 2/20 0.45
FLT3 P36888 1/20 0.44
PRKCI P41743 1/20 0.44
ABL1 P00519 3/20 0.43
NTRK1 P04629 2/20 0.43
YES1 P07947 2/20 0.43
PIM1 P11309 2/20 0.43
MAPK1 P28482 2/20 0.43
HIPK1 Q86Z02 2/20 0.43
CDK2 P24941 1/20 0.43
CDK9 P50750 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31655675 0.84 FGFR3 (0.61) KDRFGFR3FGFR1FGFR2FGFR4
SCHEMBL22149115 0.84 FGFR3 (0.61) KDRFGFR3FGFR1FGFR2FGFR4
SCHEMBL31655614 0.79 FGFR3 (0.49) KDRFGFR3FGFR1FGFR2FGFR4
SCHEMBL22149351 0.79 FGFR3 (0.49) KDRFGFR3FGFR1FGFR2FGFR4
SCHEMBL22149113 0.79 FGFR3 (0.54) KDRFGFR3ADRB1FGFR1FGFR2
SCHEMBL31655639 0.79 FGFR3 (0.54) KDRFGFR3ADRB1FGFR1FGFR2
SCHEMBL31655655 0.79 FGFR3 (0.54) KDRFGFR3ADRB1FGFR1FGFR2
SCHEMBL22149114 0.79 FGFR3 (0.54) KDRFGFR3ADRB1FGFR1FGFR2
SCHEMBL16421990 0.76 FGFR3 (0.65) KDRFGFR3FGFR1FGFR2FGFR4
SCHEMBL22122134 0.75 FGFR3 (0.69) KDRFGFR3FGFR1FGFR2FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12351571-B2 Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases ARRAY BIOPHARMA INC. (US) 2025-07-08 US disclosed
WO-2020131674-A1 7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER ARRAY BIOPHARMA INC. (US) 2020-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12351571-B2 Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases FGFR3, FGFR4, FGFR1 KDR 253/4885FGFR3 1/4885HTR7 3441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.